Sage Journals: Discover world-class research

Abstract

Antibiotic resistance has been increasing at an alarming rate in the United States and globally for decades, but the problem has only recently gained broad attention at the highest levels of the US government. More and more patients are dying of infections that do not respond to antibiotics that are currently available. Meanwhile, the antibacterial product pipeline remains fragile in part because of a lack of commercial interest from pharmaceutical companies. The Biomedical Advanced Research and Development Authority (BARDA) Broad Spectrum Antimicrobials (BSA) program leads the US government's effort to bridge this gap by advancing new antibacterials through late stages of clinical development. Other commentators have described in detail BARDA's structure, process, and role in antibacterial development. This commentary offers a public policy perspective on the emerging politics of antibiotic resistance in the context of US biosecurity politics and medical countermeasure (MCM) development. It identifies promising developments and difficult challenges that together will ultimately determine whether BARDA can become a global leader for antibiotic development.

Antibiotic resistance has been increasing at an alarming rate, but the problem has only recently gained broad attention at the highest levels of the US government. The antibacterial product pipeline remains fragile in part because of a lack of commercial interest from pharmaceutical companies. The Biomedical Advanced Research and Development Authority (BARDA) Broad Spectrum Antimicrobials (BSA) program leads the US government's effort to bridge this gap by advancing new antibacterials through late stages of clinical development. This article offers a public policy perspective on the emerging politics of antibiotic resistance in the context of US biosecurity policies and medical countermeasure (MCM) development. It identifies promising developments and difficult challenges that will ultimately determine whether BARDA can become a global leader for antibiotic development.

Get full access to this article

View all access options for this article.

References

Toner

, Adalja

, Gronvall

, Cicero

, Inglesby

. Antimicrobial resistance is a global health emergency. Health Secur, 2015; 13(3):153-155.

Allen

, Trachsel

, Looft

, Casey

. Finding alternatives to antibiotics. Ann N Y Acad Sci, 2014; 1323:91-100.

Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. April 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed August 8, 2015.

World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. April 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed August 8, 2015.

Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review on Antimicrobial Resistance, chaired by Jim O'Neill. December 2014. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed August 8, 2015.

Builder

. Antimicrobial Resistance as an Emerging Threat to National Security. Washington, DC: Atlantic Council; 2014. http://www.atlanticcouncil.org/images/files/Antimicrobial_Resistance_as_an_Emerging_Threat_to_National_Security.pdf. Accessed October 7, 2015.

Gostin

, Fidler

. Biosecurity under the rule of law. Case W Res J Int'l L, 2007; 38(3/4):437-478.

Perez

, Van Duin

. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med, 2013; 80(4):225-233.

Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep, 2013; 62(9):165-170.

10.

Falagas

, Tansarli

, Karageorgopoulos

, Vardakas

. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis, 2014; 20(7):1170-1175.

11.

Fidler

, Gostin

. Biosecurity in the Global Age: Biological Weapons, Public Health, and the Rule of Law. Palo Alto, CA: Stanford University Press; 2008.

12.

Koblentz

. Biosecurity reconsidered: calibrating biological threats and responses. Int Secur, 2010; 34(4):96-132.

13.

Committee on Advances in Technology and the Prevention of Their Application to Next Generation Biowarfare Threats, National Research Council. Globalization, Biosecurity, and the Future of the Life Sciences. Washington, DC: National Academies Press; 2006.

14.

Elbe

, Roemer-Mahler

, Long

. Medical countermeasures for national security: a new government role in the pharmaceuticalization of society. Soc Sci Med, 2015; 131:263-271.

15.

Monaco

. Opening session at the White House Forum on Antibiotic Stewardship; June 2, 2015.

16.

Rambhia

, Gronvall

. Antibiotic resistance. Biosecur Bioterror, 2009; 7(4):371-377.

17.

Boddie

, Watson

, Ackerman

, Gronvall

. Assessing the bioweapons threat: is there a foundation of agreement among experts about risk?. Science, 2015; 349(6250):792-793.

18.

Peterson

. Epidemic disease and national security. Security Studies, 2002; 12(2):43-81.

19.

42 U.S.C. § 247d-7e (2012) (enacted via Title IV of the Pandemic and All-Hazards Preparedness Act, Pub. L. No. 109-417).

20.

US Department of Health and Human Services. BARDA Strategic Plan 2011-2016. 2011. http://www.phe.gov/about/barda/Documents/barda-strategic-plan.pdf. Accessed August 9, 2015.

21.

Eichberg

. Public funding of clinical-stage antibiotic development in the United States and European Union. Health Secur, 2015; 13(3):156-165.

22.

Larsen

. BARDA's Broad Spectrum Antimicrobial (BSA) Program. Presentation to the President's Council of Advisors on Science and Technology (PCAST); March. 2015. https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/Larsen,%20Joe.pdf. Accessed August 9, 2015.

23.

US Department of Health and Human Services. 2014 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan. 2014. http://www.phe.gov/Preparedness/mcm/phemce/Documents/2014-phemce-sip.pdf. Accessed August 12, 2015.

24.

Larsen

. Presentation to U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR), convened by the Infectious Diseases Society of America (IDSA). August 2015. (Webinar archived and on file with author.)

25.

Interview with Joe Larsen, Deputy Director, Division of CBRN Medical Countermeasures, BARDA, Arlington, VA; June 25, 2015.

26.

Exec. Order No. 13676, 184 C.F.R. 56931 (2014).

27.

The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria. March 2015. https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. Accessed August 9, 2015.

28.

Innovative Medicines Initiative. New Drugs 4 Bad Bugs. http://www.imi.europa.eu/sites/default/files/uploads/documents/projects/ND4BB_overview.pdf. Accessed August 9, 2015.

29.

HHS enters into strategic alliance to accelerate new antibiotic development [press release]. US Department of Health and Human Services. September 16, 2015. http://www.hhs.gov/news/press/2015pres/09/20150916a.html. Accessed October 7, 2015.

30.

The White House. Fact Sheet: President's 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health [press release]. January 27, 2015. https://www.whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a. Accessed August 9, 2015.

31.

Owens

, Arneil

. The human security paradigm shift: a new lens on Canadian foreign policy? Report of the University of British Columbia symposium on human security. Canadian Foreign Policy Journal, 1999; 7(1):1-12.

32.

Executive Office of the President, President's Council of Advisors on Science and Technology. Report to the President on Combating Antibiotic Resistance. September 2014. http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf. Accessed August 10, 2015.

33.

Medical and Public Health Preparedness and Response: Are We Ready for Future Threats?

Before the S. Health Ed. Labor & Pens. Comm., 114th Cong. (2015).

34.

S. Rep. No. 114-74, at 14(2015).

35.

H.R. Rep. No. 114-195, at 113 (2015).

36.

Center for Responsive Politics. Alliance for Biosecurity. http://www.opensecrets.org/lobby/clientsum.php?id=D000046672&year=2014. Accessed August 9, 2015.

37.

Alliance for Biosecurity. Our members. http://www.allianceforbiosecurity.org/#!contact/c1d94. Accessed August 9, 2015.

38.

Antimicrobial Innovation Alliance. Key Issues: Incentives. http://www.antimicrobialalliance.com/incentives/. Accessed August 9, 2015.

39.

Kesselheim

, Outterson

. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics, 2011; 11(1):101-167.

40.

Hoffman

, Outterson

. Introduction: what will it take to address the global threat of antibiotic resistance?. J Law Med Ethics, 2015; 43(Suppl 3):6-11.

41.

Six Years After Anthrax: Are We Better Prepared to Respond to Bioterrorism?: Hearing Before the S. Comm. on Homeland Sec. and Gov. Aff's., 110th Cong. (2007) (statement of Tara O'Toole, Director, Center for Biosecurity of UPMC).

The ABCs of the US Broad Spectrum Antimicrobials Program: Antibiotics,Biosecurity,and Congress

Abstract

Get full access to this article

References